Mylan unveils generic Lipitor tablets in Europe

The generic version of Pfizer’s Lipitor is indicated to prevent cardiovascular disease and hypercholesterolemia.

Mylan CEO Heather Bresch said, "Mylan’s launch of Atorvastatin Calcium Tablets will help to provide health care systems in these markets with an estimated $700 million (euro 500 million) of savings in 2012 associated with the generic availability of this important medicine."

Each country’s respective health authorities have granted marketing authorization to Mylan to sell the product.

According to IMS Health, Lipitor had total sales of $1.6bn (euro 1.126bn) for the twelve months ending 31December 2011 in France, Belgium, the UK, the Netherlands and Ireland.